Mukund Paravasthu Sells 5,377 Shares of NovoCure (NASDAQ:NVCR) Stock

NovoCure Limited (NASDAQ:NVCR) COO Mukund Paravasthu sold 5,377 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $13.31, for a total value of $71,567.87. Following the completion of the sale, the chief operating officer directly owned 116,078 shares in the company, valued at approximately $1,544,998.18. The trade was a 4.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Mukund Paravasthu also recently made the following trade(s):

• On Thursday, March 5th, Mukund Paravasthu sold 43,246 shares of NovoCure stock. The shares were sold at an average price of $13.77, for a total transaction of $595,497.42.

NovoCure Trading Up 6.0%

Shares of NVCR stock traded up $0.81 during trading hours on Thursday, hitting $14.23. 2,315,394 shares of the company were exchanged, compared to its average volume of 2,231,897. The firm has a fifty day moving average of $12.73 and a 200 day moving average of $12.70. The company has a quick ratio of 1.50, a current ratio of 2.90 and a debt-to-equity ratio of 0.70. NovoCure Limited has a 1 year low of $9.82 and a 1 year high of $21.55. The firm has a market cap of $1.62 billion, a PE ratio of -11.66 and a beta of 0.71.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.19. The company had revenue of $174.35 million for the quarter, compared to the consensus estimate of $174.40 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. NovoCure’s revenue was up 8.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.61) earnings per share. Analysts expect that NovoCure Limited will post -1.3 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on NVCR. Wedbush reiterated a “neutral” rating and set a $18.00 target price on shares of NovoCure in a report on Thursday, January 15th. Evercore set a $20.00 price objective on shares of NovoCure in a research note on Monday, January 5th. HC Wainwright raised their target price on shares of NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NovoCure in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $26.93.

Institutional Investors Weigh In On NovoCure

A number of large investors have recently added to or reduced their stakes in the company. Kera Capital Partners Inc. lifted its holdings in NovoCure by 84.4% in the 4th quarter. Kera Capital Partners Inc. now owns 19,691 shares of the medical equipment provider’s stock worth $244,000 after buying an additional 9,015 shares in the last quarter. Corient Private Wealth LLC increased its position in shares of NovoCure by 178.0% during the fourth quarter. Corient Private Wealth LLC now owns 97,368 shares of the medical equipment provider’s stock worth $1,259,000 after acquiring an additional 62,341 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its position in shares of NovoCure by 14.5% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 32,660 shares of the medical equipment provider’s stock worth $422,000 after acquiring an additional 4,124 shares during the last quarter. Empowered Funds LLC acquired a new position in shares of NovoCure in the fourth quarter worth about $33,000. Finally, XTX Topco Ltd lifted its stake in shares of NovoCure by 159.2% in the fourth quarter. XTX Topco Ltd now owns 58,795 shares of the medical equipment provider’s stock worth $760,000 after acquiring an additional 36,111 shares in the last quarter. 84.61% of the stock is owned by institutional investors and hedge funds.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.